topic

415 Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study
Kunkun Li, Xiao Yang, Wei Luo, Qiang Ma, Yingjian Wang, Yanli Xiong, Xiaolong Zhao, Xianfeng Lu, Tao Bao, Wei Guo, Mengxia Li

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A253; DOI: 10.1136/jitc-2020-SITC2020.0415
417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors
Gregory Durm, Sophia Frentzas, Erik Rasmussen, Saltanat Najmi, Nooshin Sadraei

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A254; DOI: 10.1136/jitc-2020-SITC2020.0417
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors
Cathy Eng, Joaquina Baranda, Matthew Taylor, Michael Gordon, Ursula Matulonis, Filip Janku, Martin Kornacker, Asha Kamat, Oliver Rosen, Antonio Jimeno, Cathy Eng

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A254-A255; DOI: 10.1136/jitc-2020-SITC2020.0418
419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial
Sarina Piha-Paul, Tara Mitchell, Solmaz Sahebjam, Janice Mehnert, Thomas Karasic, Kevin O’Hayer, Ryan Geschwindt, Susan Spitz, Hao Liu, Johanna Bendell

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A255; DOI: 10.1136/jitc-2020-SITC2020.0419
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
Francesca Aroldi, Joseph Sacco, Kevin Harrington, Anna Olsson-Brown, Pablo Nanclares, Lavita Menezes, Praveen Bommareddy, Suzanne Thomas, Howard Kaufman, Selda Samakoglu, Robert Coffin, Mark Middleton

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A256-A257; DOI: 10.1136/jitc-2020-SITC2020.0421
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab, Scott Tykodi, Gregory Daniels, Michele Maio, Brendan Curti, Karl Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel Cho, Shanhong Guan, Erika Puente, Ute Hoch, Sue Currie, Tuan Nguyen, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael Hurwitz

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A256; DOI: 10.1136/jitc-2020-SITC2020.0420
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts
Mark Middleton, Francesca Aroldi, Joseph Sacco, Mohammed Milhem, Brendan Curti, Ari VanderWalde MBioeth, Scott Baum, Adel Samson, Anna Pavlick, Jason Chesney, Jiaxin Niu, Terence Rhodes, Tawnya Bowles, Robert Conry, Anna Olsson-Brown, Douglas Earl Laux, Howard Kaufman, Praveen Bommareddy, Alex Deterding, Selda Samakoglu, Robert Coffin, Kevin Harrington

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A257; DOI: 10.1136/jitc-2020-SITC2020.0422
426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
Reinhard Dummer, Georgina V Long, Anna Pavlick, Michael Postow, Antoni Ribas, Caroline Robert, Richard A Scolyer, Janis Taube, Michael Tetzlaff, Jason Liao, Sama Ahsan, Scott Diede, Hussein Tawbi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A259; DOI: 10.1136/jitc-2020-SITC2020.0426
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
Karl Lewis, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Zeynep Eroglu, Anne Lynn Chang, Michael Migden, Siyu Li, Kosalai Mohan, Ebony Coates, Emmanuel Okoye, Jean-François Baurain, Oliver Bechter, Axel Hauschild, Marcus Butler, Leonel Hernandez-Aya, Lisa Licitra, Rogerio Neves, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Israel Lowy, Timothy Bowler, Matthew Fury

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A260-A261; DOI: 10.1136/jitc-2020-SITC2020.0428
427 A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced melanoma
Jayanshu Jain, Melanie Frees, Hesham Yasin, Jaime Bonner, Michele Freesmeier, Rohan Garje, Vyshak Alva Venur, Mohammed Milhem, Yousef Zakharia

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A260; DOI: 10.1136/jitc-2020-SITC2020.0427

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages